文献速递浆细胞疾病淋巴瘤白血病

CAR-T细胞治疗血液系统恶性肿瘤:临床试验比例的系统评价与Meta分析

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials.
PubMed 文献 · Am J Hematol · 2026-01-09

该Meta分析纳入截至2025年7月23日发表的1/2、2和3期临床试验,评估CAR-T细胞治疗3281例复发/难治性血液系统恶性肿瘤患者的安全性和疗效。多发性骨髓瘤、高级别淋巴瘤和白血病的汇总ORR分别为89%、76%和78%,≥CR率分别为53%、55%和70%,但CRS、感染和≥3级中性粒细胞减少等不良事件常见,需密切监测。

要点

  • 多发性骨髓瘤CAR-T汇总ORR 89%、≥CR率53%,1年OS 84%、PFS 60%。
  • 高级别淋巴瘤CAR-T汇总ORR 76%、≥CR率55%,1年OS 65%、PFS 46%。
  • 白血病CAR-T汇总ORR 78%、≥CR率70%,但≥3级中性粒细胞减少和贫血常见。

核心结论

  • CAR-T细胞是复发血液系统恶性肿瘤的高效治疗选择,但需密切监测治疗相关毒性。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,纳入截至2025年7月23日发表的1/2、2和3期临床试验,共3281例复发/难治性经治血液系统恶性肿瘤患者。

主要发现

  • 11项多发性骨髓瘤试验:汇总ORR 89%、≥CR率53%、1年OS 84%、1年PFS 60%。
  • 23项高级别淋巴瘤试验:汇总ORR 76%、≥CR率55%、1年OS 65%、1年PFS 46%。
  • 16项白血病记录:汇总ORR 78%、≥CR率70%、1年OS 61%、1年PFS 40%。
  • 多发性骨髓瘤:任何级别CRS 89%、感染46%、≥3级中性粒细胞减少88%。
  • 高级别淋巴瘤:任何级别CRS 46%、≥3级中性粒细胞减少56%;白血病:任何级别CRS 85%、感染29%、≥3级中性粒细胞减少70%、≥3级贫血69%。

关键数值与推荐

  • 多发性骨髓瘤汇总ORR 89%、≥CR率53%、1年OS 84%、1年PFS 60%。
  • 高级别淋巴瘤汇总ORR 76%、≥CR率55%、1年OS 65%、1年PFS 46%。
  • 白血病汇总ORR 78%、≥CR率70%、1年OS 61%、1年PFS 40%。

临床怎么用

  • CAR-T治疗复发/难治性血液肿瘤疗效显著,应密切监测CRS、感染及≥3级中性粒细胞减少和贫血等毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This meta-analysis examined the safety and efficacy of CAR T-cell therapy in 3281 patients with hematological malignancies enrolled in phase 1/2, 2 and 3 clinical trials, published until July 23, 2025 according to the PRISMA guidelines. All trials involved relapsed/refractory, pretreated individuals. In 11 multiple myeloma trials, CAR T-cell therapy showed significant efficacy, with pooled ORR and ≥CR rates of 89% and 53%, respectively. These responses translated into important survival benefits, with 1-year OS and PFS rates of 84% and 60%, respectively. However, AEs including any-grade CRS, infections and grade ≥ 3 neutropenia emerged in pooled rates of 89%, 46% and 88%, respectively. In 23 trials on high-grade lymphomas, the pooled ORR was 76% and the pooled ≥CR rate 55%. The pooled 1-year OS and PFS rates were 65% and 46%, respectively. Any-grade CRS was prevalent in a pooled rate of 46% and grade ≥ 3 neutropenia in 56%. Data from 16 records investigating CAR T-cells for leukemia yielded pooled ORR and ≥CR rates of 78% and 70%, respectively, with pooled 1-year OS and PFS rates being 61% and 40%, respectively. Similarly to myeloma and lymphoma, any-grade CRS was very common at a pooled rate of 85% and any-grade infections occurred at a pooled rate of 29%. Apart from grade ≥ 3 neutropenia (70%), grade ≥ 3 anemia emerged as an equally common serious hematological AE (69%). In conclusion, CAR T-cells constitute a highly effective therapeutic option for patients with hematological cancer at relapse, but close patient monitoring is essential to address treatment-related toxicities.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Filippatos C, Kanteli I, Pasipoularidou DG, et al. Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials. Am J Hematol. 2026. PMID: 41510841. doi:10.1002/ajh.70201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。